Dexcom vs Idexx Laboratories
Dexcom and Idexx Laboratories are similar in size: $4.66bn and $4.30bn of revenue in their latest fiscal years. Dexcom grew faster (15.6% against 10.4%). Idexx Laboratories kept more of each dollar of sales as profit: a net margin of 24.6% against 17.9%. Dexcom carries less debt relative to equity (45.2% against 52.8%).
| Latest fiscal year | DexcomDXCM, 2025 | Idexx LaboratoriesIDXX, 2025 |
|---|---|---|
| Revenue | $4.66bn | $4.30bn |
| Revenue growth | 15.6% | 10.4% |
| Net income | $836m | $1.06bn |
| Operating margin | 19.6% | 31.6% |
| Net margin | 17.9% | 24.6% |
| Return on equity | 34.5% | 66.2% |
| Free cash flow | $1.08bn | $1.06bn |
| Cash | $918m | $180m |
| Total debt | $1.24bn | $848m |
| Debt to equity | 45.2% | 52.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $500m | $1.22bn |
| Employees | 11,100 | 11,000 |
| Market value | $31.01bn | $53.19bn |
| Price vs our value range | Within our value range | Above our value range |
| Moat score | 56 (Moderate) | 97 (Strong) |
| Insider trades, 12 months | 2 buys, 32 sales | 0 buys, 36 sales |